CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The firm mainly conducts its business in the domestic market.
最新の財務諸表(Form-10K)によると、Gaensel Energy Group Incの総資産は$0で、純損失は$0です。
CASIの主要な財務比率は何ですか?
Gaensel Energy Group Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
CASI Pharmaceuticals Incの収益はセグメントまたは地域別にどのように分けられていますか?
Gaensel Energy Group Inc の最大収益セグメントは Product で、最新の利益発表における収益は 25,029,292 です。地域別に見ると、United States が Gaensel Energy Group Inc の主要市場であり、収益は 25,880,048 です。
CASI Pharmaceuticals Incは収益を上げていますか?
いいえ、最新の財務諸表によると、Gaensel Energy Group Incの純損失は$0です。